The US federal government has cleared the proposed sale of California-based Complete Genomics to China's BGI-Shenzen, The New York Times reports. The acquisition was given the OK by Committee on Foreign Investment in the United States, which examines the national security ramification of sales of US companies to foreign buyers. The Times adds that the Federal Trade Commission still needs to green-light the deal on antitrust grounds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in PNAS

Different Approach

All of It

The Foods You Eat

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.